Bring the potential of ROZLYTREK® to life
ROZLYTREK
offers convenient
once-daily,
oral dosing1
![hero-mobile-text.jpg](https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/images/hero-mobile-text.jpg?wid=600&fit=constrain,0 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/images/hero-mobile-text.jpg?wid=1200&fit=constrain,0 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/images/hero-mobile-text.jpg?wid=1920&fit=constrain,0 1920w)
ROZLYTREK offers convenient once-daily, oral dosing1
- The recommended dose for adults is 600 mg orally once-daily
- ROZLYTREK can be taken with or without food
ROZLYTREK dosing
Dosing
Paediatric dosing1
![ROZLYTREK paediatric dosing table according to body surface area](https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/images/prescribing-img-1.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/images/prescribing-img-1.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/images/prescribing-img-1.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
ROZLYTREK dosing modifications
Temporary interruption, dose reduction or discontinuation of treatment with ROZLYTREK may help manage adverse reactions1
Dose Reduction Schedule of ROZLYTREK for Paediatric Patients BSA of 1.11 m2 to 1.50 m2
Starting Dose
![icon-tabs-3.png](https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-3.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-3.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-3.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
400 mg once-daily
First Reduction
![icon-tabs-2.png](https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-2.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-2.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-2.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
300 mg once-daily
Second Reduction
![icon-tabs-1.png](https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-1.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-1.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-1.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
200 mg, for 5 days each week (Monday, Wednesday, Friday, Saturday, Sunday)
Dose Reduction Schedule of ROZLYTREK for Adult Patients and Paediatric Patients BSA ≥ 1.51 m2
Starting Dose
![icon-tabs-3.png](https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-3.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-3.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-3.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
600 mg once-daily
First Reduction
![icon-tabs-2.png](https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-2.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-2.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-2.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
400 mg once-daily
Second Reduction
![icon-tabs-1.png](https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-1.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-1.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/icons/icon-tabs-1.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
200 mg once-daily
![Dose reduction table for ROZLYTREK adverse events: congestive heart failure, cognitive disorders](https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/images/Table-2-v2.png?wid=600&fit=constrain,0&fmt=png-alpha 600w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/images/Table-2-v2.png?wid=1200&fit=constrain,0&fmt=png-alpha 1200w, https://roche-h.assetsadobe2.com/is/image/content/dam/rozlytrek-2/en/images/Table-2-v2.png?wid=1920&fit=constrain,0&fmt=png-alpha 1920w)
ROZLYTREK SmPC
Download the ROZLYTREK Summary of Product Characteristics
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for details on how to report adverse reactions.
Footnotes
ALT, alanine aminotransferase; AR, adverse reaction; AST, aspartate aminotransferase; BSA, body surface area; ms, millisecond; QT, time from the start of the Q wave to the end of the T wave; QTc, the corrected QT interval; SmPC, summary of product characteristics; ULN, upper limit of normal.
References
- ROZLYTREK Summary of Product Characteristics, 2020.